- Sangamo Therapeutics enters a lucrative licensing agreement with Eli Lilly, propelling stock by 28% in after-hours trading.
- Analysts project significant upside potential with a price target averaging $5.00 per share.
- Sangamo’s current valuation suggests a substantial opportunity for investors based on GuruFocus estimates.
Sangamo Therapeutics (SGMO, Financial) recently announced a strategic licensing agreement with Eli Lilly, allowing the pharmaceutical giant access to its proprietary STAC-BBB virus capsid. This breakthrough collaboration aims to advance genomic therapies addressing central nervous system disorders. Sangamo will benefit from an upfront payment of $18 million and stands to gain up to $1.4 billion through milestone payments and potential royalties. This news invigorated the market, causing Sangamo's stock to surge approximately 28% in after-hours trading.
Wall Street Analysts Forecast
According to insights from six top analysts, Sangamo Therapeutics Inc (SGMO, Financial) is poised for a substantial rise. The average 12-month price target stands at $5.00, with projections ranging from a high of $10.00 to a low of $2.00. Given the stock's current trading price of $0.62, this implies an impressive potential upside of 703.47%. Interested readers can explore more detailed analyst estimates on the Sangamo Therapeutics Inc (SGMO) Forecast page.
Brokerage firms echo this optimism, with eight analysts rating Sangamo Therapeutics Inc's (SGMO, Financial) average recommendation at 2.3, denoting an "Outperform" status. The brokerage consensus suggests confidence in the stock's performance, rated on a scale from 1 (Strong Buy) to 5 (Sell).
GuruFocus Valuation Insights
For investors seeking a deeper understanding of Sangamo Therapeutics' intrinsic value, GuruFocus provides a compelling estimated GF Value of $1.17 within the next year. This estimation projects an 88.01% upside from the current share price of $0.6223. The GF Value represents the stock's fair trading value, derived from historical trading multiples, past business growth, and future business performance forecasts. For an in-depth analysis, visit the Sangamo Therapeutics Inc (SGMO, Financial) Summary page.
